Filter Results

Clinical Studies

Open

  • Tumor Molecular Analysis Jacksonville, Fla.

    The purpose of this study is to develop preclinical models that include cell lines and patient derived xenografts (PDX) that include molecular characterization and testing novel therapies in these preclinical models. Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models have not been cross contaminated during the development process with other ongoing lines. Tissue microarray and immunohistochemical (IHC) analysis will also be performed on cell lines, PDX and patient tissues to identify potential molecular targets for therapy.

    For patients who consented, patient clinical therapy response data may be correlated with preclinical response data in cell lines and PDX models. 

Closed for Enrollment

  • Collection Of Mayo SDH Mutant Paraganglioma Tumor Tissue For Establishment Of Cultured Tumor Cell Lines Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to to develop cultured human tumor cell lines from paraganglioma/ pheochromocytoma (PGL) tumors. 
  • Genitourinary (GU) Tumor Molecular Analysis Jacksonville, Fla.

    This study is being done to collect and store samples of genitourinary (GU) tissues (and potentially blood) for current and future research studies on (GU) diseases.
  • Tumor Molecular Analysis Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to develop preclinical models that include cell lines and patient derived xenografts (PDX) that include molecular characterization and testing novel therapies in these preclinical models. Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models have not been cross contaminated during the development process with other ongoing lines. Tissue microarray and immunohistochemical (IHC) analysis will also be performed on cell lines, PDX and patient tissues to identify potential molecular targets for therapy.

    For patients who consented, patient clinical therapy response data may be correlated with preclinical response data in cell lines and PDX models. 
.